Results 11 to 20 of about 6,272,020 (179)

John Cunningham virus T-antigen expression in anal carcinoma† [PDF]

Cancer, 2011
AbstractBACKGROUND:Anal carcinoma is thought to be driven by human papillomavirus (HPV) infection through interrupting function of cell regulatory proteins such as p53 and pRb. John Cunningham virus (JCV) expresses a T‐antigen that causes malignant transformation through development of aneuploidy and interaction with some of the same regulatory ...
Ajay Goel, John M Carethers, Sonia Ramamoorthy   +2 more
exaly   +6 more sources

John Cunningham Virus seroconversion during natalizumab treatment

ABCS Health Sciences
Introduction: Multiple sclerosis is a progressive disease that is difficult to predict, originating in cases of disability. Natalizumab is a highly effective disease-modifying therapy but is associated with greater John Cunningham virus (JCV ...
Erica Freire de Vasconcelos-Pereira, Vanessa Marcon de Oliveira, Cristiane Munaretto Ferreira, Giovanna Arisa Tano de Paula, Maria Tereza Ferreira, Pedro Rippel Salgado, João Américo Domingos, Massaco Satomi, Fabiany Monteiro da Silva, Camila Yamanaka Akamine, Vanessa Terezinha Gubert   +10 more
doaj   +2 more sources

Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis [PDF]

Arquivos de Neuro-Psiquiatria, 2018
Treatment options for multiple sclerosis (MS) have changed over the last few years, bringing about a new category of drugs with more efficient profiles. However, these drugs have come with a whole new profile of potential adverse events that neurologists
Luciana Prats Branco, Tarso Adoni, Samira Luisa Apostolos-Pereira, Joseph Bruno Bidin Brooks, Eber Castro Correa, Carlos Augusto Damasceno, Audred Cristina Biondo Eboni, Leticia Fezer, Paulo Diniz da Gama, Marcus Vinicius Magno Goncalves, Sidney Gomes, Anderson Kuntz Grzesiuk, Maria Fernanda Mendes, Rogerio Rizo Morales, Andre Muniz, Monica Fiuza Koncke Parolin, Maria Lucia Vellutini Pimentel, Marlise de Castro Ribeiro, Gutemberg Augusto Cruz dos Santos, Henry Koiti Sato, Simone Batista Scherpenhuijzen, Claudio Scorcine, Fabio Siquineli, Nise Alexandra de Carvalho Sousa, Daniel Lima Varela, Tereza Cristina Avila Winckler, Yara Dadalti Fragoso   +26 more
doaj   +4 more sources

Oncogenic Potential of John Cunningham Virus (JCV) in Human Infection and Cancer Development [PDF]

Pharmaceutical and Biomedical Research
Background: The John Cunningham virus (JCV), a prevalent and asymptomatic virus, can cause neurological complications, such as progressive multifocal leukoencephalopathy (PML) in immunocompromised individuals.
Abolfazl Jafari-Sales, Kosar Hosseini-Karkaj, Mehrdad Pashazadeh   +2 more
doaj   +2 more sources

A Chronic Lymphocytic Leukemia Patient with Progressive Multifocal Leukoencephalopathy Caused by John Cunningham Virus

Acta Medica Indonesiana, 2018
Progressive multifocal leukoencephalopathy (PML) is a rare but fatal disease leading to severe neurological impairments. PML is a clinical manifestation, which is usually associated with John Cunningham virus (JCV) infection.
Pristya Ramadhani, Bramantono Bramantono, Made Putra Sedana   +2 more
doaj   +5 more sources

A Case of John Cunningham Virus Induced Rhombencephalitis after Rituximab Therapy for Idiopathic Thrombocytopenic Purpura. [PDF]

Case Rep Infect Dis, 2021
Background. John Cunningham virus (JCV) is known to cause progressive multifocal leukoencephalopathy (PML) in immuno-compromised patients due to lytic infection of oligodendrocytes and astrocytes. Rarely, it may also present as granule cell neuronopathy (GCN), leading to degeneration of cerebellar granule cell neurons.
Katragadda S, Koneru V, Devany G, DeWitt AS, Tati VH.   +4 more
europepmc   +5 more sources

Changes in John Cunningham Virus Index in Multiple Sclerosis Patients Treated with Different Disease-Modifying Therapies. [PDF]

Curr Neuropharmacol, 2022
Background: Progressive Multifocal Leukoencephalopathy (PML) is an opportunistic infection caused by John Cunningham virus (JCV) reactivation, potentially associated with natalizumab (NTZ) treatment for Multiple Sclerosis (MS). The anti-JCV antibodies titre (JCV index) increases during NTZ treatment; however, the effects of other disease-modifying ...
Sgarlata E, Chisari CG, Toscano S, Finocchiaro C, Lo Fermo S, Millefiorini E, Patti F.   +6 more
europepmc   +3 more sources

Stroke Mimics: A Case of John Cunningham Virus-Induced Progressive Multifocal Leukoencephalopathy. [PDF]

Cureus
Progressive multifocal leukoencephalopathy (PML) is a rare, often fatal neurological disorder caused by the John Cunningham virus (JCV). It affects immunocompromised individuals, leading to brain demyelination. Diagnosis involves MRI scans and JCV detection in cerebrospinal (CSF) fluid.
Kamran HS, Khan A, Ling CSB, Kausar S.
europepmc   +3 more sources

Genotypes of John Cunningham (JC) Virus Urinary Excretion in Pregnant and Non-Pregnant Women in Isfahan, Iran

Journal of Family and Reproductive Health, 2018
Objective: To evaluate presence of different subtypes and genetic variations of JC virus in different geographical areas is a useful tool for reconstructing of the genetic information and understanding of the evolution of the virus and also in tracing of
Sayyedeh Rahmaneh Atyabi, Majid Bouzari, Majid Komijani   +2 more
doaj   +2 more sources

Favorable Response to Mirtazapine in John Cunningham Virus-related Gray Matter Lesion in a Patient with Human Immunodeficiency Virus. [PDF]

Cureus, 2019
Mirtazapine has recently emerged as a promising agent for the treatment of progressive multifocal leukoencephalopathy (PML). While there is no Class I evidence for its use, numerous case reports have illustrated mirtazapine's efficacy. True to its name, PML is known to occur mostly in the white matter of the brain as its causative agent, John ...
Alwehaibi AI, AlJaber MI, Nahrir S.
europepmc   +4 more sources